FibroGen
FGEN | NASDAQ
$9.07
-$0.15 (-1.63%)
At close: Jan 12, 2026, 09:30 AM ET
FibroGen Company Profile
Company profile explainedCompany Profile
FibroGen, Inc. is a biopharmaceutical firm dedicated to discovering, developing, and bringing to market therapies that address significant medical conditions currently lacking effective treatments. Among its pipeline, FibroGen is advancing Roxadustat, an orally administered small molecule that inhibits hypoxia inducible factor prolyl hydroxylases. This drug has successfully completed Phase III clinical trials in the US, Europe, China, and Japan for treating anemia in chronic kidney disease, and is currently in Phase II/III development in China for anemia linked to myelodysplastic syndromes. Additionally, the company is progressing Pamrevlumab, a human monoclonal antibody designed to block connective tissue growth factor. Pamrevlumab is undergoing Phase III clinical development for multiple conditions including idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, with a separate Phase III trial also underway for Duchenne muscular dystrophy. FibroGen maintains strategic collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. Established in 1993, FibroGen, Inc. operates from its headquarters in San Francisco, California.
Key Executives
| Name | Position |
|---|---|
| Thane Wettig | Chief Executive Officer & Director |
| David DeLucia | Senior Vice President & Chief Financial Officer |
| Gaia Vasiliver-Shamis | Director of IR & Communications - LifeSci Advisors |
| John Alden | Corporate Secretary & General Counsel |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 01, 2026 | 8-K | Current Report |
| Sep 09, 2026 | 4 | Filing |
| Sep 09, 2026 | 4 | Filing |
| Aug 31, 2026 | 8-K | Current Report |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 13, 2026 | 10-Q | Quarterly Report |
| Aug 13, 2026 | 8-K | Current Report |
| Jun 17, 2026 | 4 | Filing |
| Jun 17, 2026 | 4 | Filing |
| Jun 17, 2026 | 4 | Filing |
FibroGen
| Country | United States |
| IPO Date | Nov 14, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 225 |
| CEO | Thane Wettig |
Contact Details
409 Illinois Street San Francisco,
California 94158 United States
Stock Details
| Ticker Symbol | FGEN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000921299 |
| CUSIP Number | 31572Q881 |
| ISIN Number | US31572Q8814 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove FGEN